Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation development and cGMP manufacture of its own psilocybin. Interim results from the PsiGAD trial remain internally confidential to maintain blinding and integrity of the trial, however, a report from the independent data safety monitoring board (DSMB) on the interim results will be released soon, when available.
Deutsche Bank Maintains Hold on Conagra Brands, Lowers Price Target to $32
Deutsche Bank analyst Steve Powers maintains Conagra Brands (NYSE:CAG) with a Hold and lowers the price target from $35 to $32.
